Cancer Blog | Cancer Education and Research Institute - Cancer Education and Research Institute

CERI Cancer Quiz Answer and Winners

4/28/2022

Hi everyone, here is the correct answer and the winner to our this week's CERI Cancer Quiz.

Topic: Head and Neck Cancer⚡

THANK YOU to all those who have participated. 👍

Also, we would like shout out a big THANK YOU to all of our supporters.
Thank you for being here and for all of your support! 🙏

Enjoy and see you all again in our next quiz! 💪

#Empowermentagainstcancer™
#CERICancerQuiz™
#canceredinstitute

Want to learn more why? Read our article here.

CERI Cancer Quiz

4/27/2022

Hey, it is CERI Cancer Quiz Day!

Write in the comment box below your answer (ONE answer per person please) to be considered as the winner shall you answer correctly!

Winners and the answer will be announced the NEXT DAY, on Thursdays!

Good Luck!

Tip: Check out our article.

CERI Cancer Quiz Answer and Winner

4/21/2022

Hi everyone, here is the correct answer and the winner to our this week's CERI Cancer Quiz.

Topic: Inflammation⚡

THANK YOU to all those who have participated. 👍

Also, we would like shout out a big THANK YOU to all of our supporters.
Thank you for being here and for all of your support! 🙏

Enjoy and see you all again in our next quiz! 💪

#Empowermentagainstcancer™
#CERICancerQuiz™
#canceredinstitute

To learn more about the correct answer as to why inflammation can cause cancer, read our article here.

CERI Cancer Quiz

4/20/2022

Hey, it is CERI Cancer Quiz Day!

Write in the comment box below your answer (ONE answer per person please) to be considered as the winner shall you answer correctly!

Winners and the answer will be announced the NEXT DAY, on Thursdays!

Good Luck!

Tip: Check out our article.

Melanoma FDA Approvals

4/19/2022

3/18/2022: FDA approved OPDUALAG™ (nivolumab and relatlimab-rmb w, Bristol-Myers Squibb) to treat unresectable or metastatic melanoma.

OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Recommended Dosage:
• Adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg: 480 mg nivolumab and 160 mg relatlimab intravenously every 4 weeks.
• Administer OPDUALAG as an intravenous infusion over 30 minutes.

Learn more in the FDA label here.

1/25/2022: FDA approved KIMMTRAK® (tebentafusp-tebn, Immunocore) to treat unresectable or metastatic uveal melanoma.

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week there after.

Learn more in the FDA label here.

CERI Cancer Quiz

4/13/2022

Hey, it is CERI Cancer Quiz Day!

Write in the comment box below your answer (ONE answer per person please) to be considered as the winner shall you answer correctly!

Winners and the answer will be announced the NEXT DAY, on Thursdays!

Good Luck!

Tip: Feel free to read our article here.

CERI Cancer Quiz Answer and Winners

4/7/2022

Hi everyone, here is the correct answer to our this week's CERI Cancer Quiz.

Topic: Balancing Blood Sugar⚡

Sadly, no winners this week!

THANK YOU to all those who have participated. 👍

Also, we would like shout out a big THANK YOU to all of our supporters.
Thank you for being here and for all of your support! 🙏

Enjoy and see you all again in our next quiz! 💪

#Empowermentagainstcancer™
#CERICancerQuiz™
#canceredinstitute

Learn more about tip on how you can balance your blood sugar here.

CERI Cancer Quiz Day

4/6/2022

Hey, it is CERI Cancer Quiz Day!

Write in the comment box below your answer (ONE answer per person please) to be considered as the winner shall you answer correctly!

Winners and the answer will be announced the NEXT DAY, on Thursdays!

Good Luck!

Beginning of Ramadan

4/2/2022

For everyone who is celebrating the beginning of Ramadan, a one month of fasting, we wish you a very healthy and peaceful month of turning inward.

Please make sure you keep eating healthy and hydrate yourself well.
Find more information on eating healthy here.

Follow us throughout the month for trusted healthy diet tips
👉 Social media: @canceredinstitute
Also visit our website: canceredinstitute.org

#CERICares

🌟🌟🌟🌟

Yes, I'd like to help CERI continue saving lives!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.

Copyright © 2013-2023 Cancer Education and Research Institute®. All Rights Reserved.
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.
Alle Rechte vorbehalten.
Powered by Cancer Education and Research Institute®